| Literature DB >> 25936695 |
Jun Zhao, Chunhui Wu1, James Abbruzzese2, Rosa F Hwang, Chun Li.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. Cyclopamine (CPA), a potent inhibitor for sonic hedgehog pathway (SHH), shows great promises in PDAC treatment, including the disruption of tumor-associated stroma, and enhancement of radiation therapy. However, CPA is insoluble in water and therefore requires a nanometric delivery platform to achieve satisfactory performance. We herein encapsulated CPA in a core-cross-linked polymeric micelle system (M-CPA). M-CPA was combined with Cs-137 radiation and evaluated in vitro in PDAC cell lines and a human pancreatic stellate cell line. The results showed that M-CPA had higher cytotoxicity than CPA, abolished Gli-1 expression (a key component of SHH), and enhanced the radiation therapy of Cs-137. M-CPA radiosensitization correlated with its ability to disrupt the repair of radiation-induced DNA damage. These findings indicate that the combination therapy of M-CPA and radiation is an effective strategy to simultaneously treat pancreatic tumors and tumor-associated stroma.Entities:
Keywords: DNA damage repair; cyclopamine; pancreatic cancer; radiation sensitization; stroma disruption
Mesh:
Substances:
Year: 2015 PMID: 25936695 PMCID: PMC5055750 DOI: 10.1021/mp500875f
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939